Ernexa Therapeutics Inc.
ERNA evidence brief
What we can confirm
- Market Cap:
- $4.9M
What it means
What to watch
Prepared research question
What matters most for ERNA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ERNA
Ernexa Therapeutics Inc. (ERNA) is a pre-revenue biotech developing engineered synthetic iMSC therapies for oncology and autoimmune diseases, with lead candidate ERNA-101 advancing toward Phase I clinical trials.
Key risk: Pre-revenue, limited cash runway
Market Cap
$4.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Ernexa Therapeutics Inc. (ERNA) is a pre-revenue biotech developing engineered synthetic iMSC therapies for oncology and autoimmune diseases, with lead candidate ERNA-101 advancing toward Phase I clinical trials.
- Lead candidate ERNA-101 is an allogeneic iMSC therapy engineered to express IL-7/IL-15 fusion cytokine, initially targeting platinum-resistant ovarian cancer [sec_mda · as of 2026-08-06].
- In July 2026, an independent CRO study reproduced earlier MD Anderson findings, demonstrating complete tumor clearance and durable long-term survival for ERNA-101 [sec_mda · as of 2026-08-06].
- IND-enabling safety studies for ERNA-101 showed no adverse findings in repeat-dose GLP toxicology and no acute toxicity [news · published 2026-09-30].
- The company reported net income of -$4.0M and shareholders' equity of $3.2M as of 2026-06-30 [sec].
- Ernexa is also developing ERNA-201, an anti-inflammatory iMSC for autoimmune disorders like rheumatoid arthritis, with positive preclinical proof-of-concept data [news · published 2026-09-15].
What works
- Independent third-party validation of ERNA-101's preclinical efficacy strengthens confidence in its mechanism of action [sec_mda · as of 2026-08-06].
- Positive IND-enabling safety results for ERNA-101 de‑risk the path to first-in-human dosing [news · published 2026-09-30].
- Successful pre-IND meeting with the FDA provided regulatory alignment for the development approach [sec_mda · as of 2026-08-06].
- Appointment of experienced oncology drug developer Dr. Robert J. Spiegel to the Board adds deep clinical and regulatory expertise [news · published 2026-09-17].
What to weigh
- The company is pre-revenue with a net loss of $4.0M and limited shareholders' equity of $3.2M as of 2026-06-30, indicating a short cash runway [sec].
- All candidates are in preclinical or IND-enabling stages; no clinical data have been generated yet [sec_mda · as of 2026-08-06].
- The company is actively seeking strategic partnerships and research grants to fund operations, highlighting financial dependency on external sources [sec_mda · as of 2026-08-06].
- Near-term resources are concentrated on ERNA-101, leaving pipeline diversification and ERNA-201 development dependent on future funding [news · published 2026-09-15].
From the filings
Quoted directly from source documents.
Independent validation of ERNA-101 preclinical efficacy
“In July 2026, an independently conducted study conducted by an independent contract research organization successfully reproduced earlier findings generated at MD Anderson Cancer Center, demonstrating complete tumor clearance and durable long-term survival in a substantially larger study.”
SEC MD&A · August 6, 2026
Positive IND-enabling safety results for ERNA-101
“Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute”
News · September 30, 2026
Pre-IND meeting with FDA resulted in regulatory alignment
“During the fourth quarter of 2025, we had a successful pre-Investigational New Drug ("IND") meeting with the Food and Drug Administration ("FDA"), which resulted in regulatory alignment with our development approach.”
SEC MD&A · August 6, 2026
Risks & what to watch (4)›
Key risks
- Pre-revenue, limited cash runway — Net loss of $4.0M and equity of $3.2M as of 2026-06-30 suggest a short cash runway without additional funding [sec].
- No clinical data yet — All candidates are preclinical; no human data exist to validate safety or efficacy in patients [sec_mda · as of 2026-08-06].
- Dependence on partnerships and grants — Company actively seeking strategic partnerships and research grants to fund operations, indicating financial vulnerability [sec_mda · as of 2026-08-06].
- Narrow pipeline focus — Resources concentrated on ERNA-101; ERNA-201 and other programs depend on future funding [news · published 2026-09-15].
What to watch
- Completion of IND-enabling studies and IND submission for ERNA-101, expected in 2026 [sec_mda · as of 2026-08-06].
- Initiation of Phase I investigator-sponsored clinical trial for ERNA-101, planned for second half of 2026 [sec_mda · as of 2026-08-06].
- Ability to secure strategic partnerships or research grants to extend cash runway [sec_mda · as of 2026-08-06].
- Further preclinical or clinical data from ERNA-201 in autoimmune models [news · published 2026-09-15].
Sources: News · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run Ernexa Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ernexa Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of Apr 28, 2026- % of float
- 1.1%
- Days to cover
- 0.2
- Shares short
- 201,143
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ERNA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Ernexa Therapeutics Inc.?
Ernexa Therapeutics Inc. (ERNA) is a pre-revenue biotech developing engineered synthetic iMSC therapies for oncology and autoimmune diseases, with lead candidate ERNA-101 advancing toward Phase I clinical trials.
Who is the CEO of Ernexa Therapeutics Inc.?
Mr. Sanjeev Luther is the chief executive officer of Ernexa Therapeutics Inc. (ERNA).
Where is Ernexa Therapeutics Inc. headquartered?
Ernexa Therapeutics Inc. (ERNA) is headquartered in Cambridge, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.